-
1 Comment
Pieris Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 31.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.0.
Pieris Pharmaceuticals, Inc's total revenue sank by 89.1% to $2M since the same quarter in the previous year.
Its net income has dropped by 1767.7% to $-14M since the same quarter in the previous year.
Finally, its free cash flow grew by 7.6% to $-14M since the same quarter in the previous year.
Based on the above factors, Pieris Pharmaceuticals, Inc gets an overall score of 3/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | US6979471090 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | None |
|---|---|
| PE Ratio | nan |
| Target Price | nan |
| Dividend Yield | nan% |
| Beta | nan |
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PI6.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
